Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.66 USD | +2.31% | -22.45% | +168.01% |
18/04 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
06/03 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Sales 2024 * | - | Sales 2025 * | 23.49M 1.96B | Capitalization | 107M 8.91B |
---|---|---|---|---|---|
Net income 2024 * | -61M -5.09B | Net income 2025 * | -54M -4.51B | EV / Sales 2024 * | - |
Net cash position 2024 * | 86M 7.18B | Net cash position 2025 * | 68M 5.67B | EV / Sales 2025 * | 1.65 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-2.48
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.61% |
Latest transcript on Rezolute, Inc.
1 day | +2.31% | ||
1 week | -22.45% | ||
Current month | +4.31% | ||
1 month | +4.31% | ||
3 months | +141.82% | ||
6 months | +170.05% | ||
Current year | +168.01% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 26/10/26 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 26/10/26 |
Daron Evans
DFI | Director of Finance/CFO | 50 | 24/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 26/10/26 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 10/19/10 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 20/19/20 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.66 | +2.31% | 203,470 |
25/24/25 | 2.6 | -10.03% | 455,095 |
24/24/24 | 2.89 | +1.05% | 343,913 |
23/24/23 | 2.86 | -19.21% | 940,007 |
22/24/22 | 3.54 | +3.21% | 333,631 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+168.01% | 107M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.08% | 22.15B | |
-17.37% | 21.02B | |
-9.28% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RZLT Stock